0001209191-23-006789.txt : 20230203
0001209191-23-006789.hdr.sgml : 20230203
20230203160923
ACCESSION NUMBER: 0001209191-23-006789
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230201
FILED AS OF DATE: 20230203
DATE AS OF CHANGE: 20230203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Laponis Adam
CENTRAL INDEX KEY: 0001827198
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39616
FILM NUMBER: 23585856
MAIL ADDRESS:
STREET 1: C/O EARGO, INC.
STREET 2: 2665 NORTH FIRST STREET, SUITE 300
CITY: SAN JOSE
STATE: CA
ZIP: 95134
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eargo, Inc.
CENTRAL INDEX KEY: 0001719395
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 273879804
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2665 NORTH FIRST STREET
STREET 2: SUITE 300
CITY: SAN JOSE
STATE: CA
ZIP: 95134
BUSINESS PHONE: 650-351-7700
MAIL ADDRESS:
STREET 1: 2665 NORTH FIRST STREET
STREET 2: SUITE 300
CITY: SAN JOSE
STATE: CA
ZIP: 95134
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-01
0
0001719395
Eargo, Inc.
EAR
0001827198
Laponis Adam
C/O EARGO, INC.
2665 NORTH FIRST STREET, SUITE 300
SAN JOSE
CA
95134
0
1
0
0
Chief Financial Officer
Stock Option (Right to Buy)
11.58
2023-02-01
4
A
0
82500
0.00
A
2033-01-31
Common Stock
82500
82500
D
Stock Option (Right to Buy)
11.58
2023-02-01
4
A
0
82500
0.00
A
2033-01-31
Common Stock
82500
82500
D
The Stock Option vests and becomes exercisable as to 20% of the shares subject to the stock option on February 15, 2024 (the "Vesting Start Date"), with the remainder vesting in 16 equal quarterly installments thereafter until all of the shares subject to the stock option have vested and become exercisable on the fourth anniversary of the Vesting Start Date, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
The Stock Option vests and becomes exercisable in full upon attainment of a 360-day VWAP (volume-weighted average price) of $20.00 for the Issuer's Common Stock on or prior to February 15, 2028, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through such date.
/s/ Christy La Pierre, Attorney-in-Fact for Adam Laponis
2023-02-03